ENDOLOGIX INC's ticker is and the CUSIP is 29266SAA4. A total of 19 filers reported holding ENDOLOGIX INC in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $49,220,000 | +6.7% | 51,117,000 | 0.0% | 1.90% | -0.1% |
| Q4 2016 | $46,140,000 | +17.6% | 51,117,000 | +24.9% | 1.90% | +4.1% |
| Q3 2016 | $39,231,000 | +3.8% | 40,941,000 | 0.0% | 1.82% | +22.9% |
| Q2 2016 | $37,787,000 | +26.5% | 40,941,000 | 0.0% | 1.48% | +16.7% |
| Q1 2016 | $29,871,000 | -13.7% | 40,941,000 | 0.0% | 1.27% | -9.3% |
| Q4 2015 | $34,602,000 | -6.2% | 40,941,000 | 0.0% | 1.40% | -1.8% |
| Q3 2015 | $36,877,000 | -7.3% | 40,941,000 | 0.0% | 1.43% | +7.7% |
| Q2 2015 | $39,784,000 | +13.0% | 40,941,000 | +17.2% | 1.32% | +16.2% |
| Q1 2015 | $35,203,000 | +1.9% | 34,925,000 | 0.0% | 1.14% | -8.2% |
| Q4 2014 | $34,562,000 | +82.6% | 34,925,000 | +64.4% | 1.24% | +80.0% |
| Q3 2014 | $18,932,000 | +51.2% | 21,240,000 | +70.6% | 0.69% | +37.2% |
| Q2 2014 | $12,520,000 | +4.9% | 12,450,000 | 0.0% | 0.50% | +3.3% |
| Q1 2014 | $11,930,000 | – | 12,450,000 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Endurant Capital Management LP | 1,541,000 | $1,498,000 | 0.56% |
| SSI INVESTMENT MANAGEMENT LLC | 2,000,000 | $1,944,000 | 0.16% |
| PALISADE CAPITAL MANAGEMENT, LP | 2,874,000 | $2,793,000 | 0.10% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 610,000 | $581,000 | 0.01% |
| AMUNDI ASSET MANAGEMENT US, INC. | 6,475,000 | $6,199,000 | 0.01% |
| Citadel Advisors | 4,080,000 | $3,953,000 | 0.00% |
| Capco Asset Management, LLC | 3,000 | $3,000 | 0.00% |
| WOLVERINE ASSET MANAGEMENT LLC | 104,000 | $100,000 | 0.00% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 3,000 | $3,000 | 0.00% |
| Bank of New York Mellon Corp | 250,000 | $246,000 | 0.00% |